Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Trial Profile

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Sensorineural hearing loss
  • Focus Registrational; Therapeutic Use
  • Acronyms AUDIBLE-S
  • Sponsors Sensorion
  • Most Recent Events

    • 21 Dec 2018 According to a Sensorion media release, this company has received authorization to conduct this trial in Europe and Canada
    • 26 Sep 2018 According to a Sensorion media release, this trial was initiated in the second half of 2018.
    • 26 Sep 2018 Status changed from not yet recruiting to recruiting, as reported in a Sensorion media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top